Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.2, 2012-02, pp. : 251-260

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Investigational therapies for non-muscle invasive bladder cancer

By Smaldone Marc C Casella Daniel P Welchons Daniel R Gingrich Jeffrey R

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 3, 2010-03 ,pp. : 371-383

Informa Healthcare

Access to resources Recommend Favorite

Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non–muscle-invasive bladder cancer

By Bachir Bassel G. Dragomir Alice Aprikian Armen G. Tanguay Simon Fairey Adrian Kulkarni Girish S. Breau Rodney H. Black Peter C. Kassouf Wassim

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2424-2431

Blackwell Publishing

Access to resources Recommend Favorite

Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the Bladder

By Brassell Stephen A. Kamat Ashish M.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 10, 2006-11 ,pp. : 1027-1036

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Intravesical therapy for bladder cancer

By Williams Steve K Hoenig David M Ghavamian Reza Soloway Mark

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 6, 2010-04 ,pp. : 947-958

Informa Healthcare

Access to resources Recommend Favorite

Intravesical valrubicin for bladder cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 268, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite